Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.

Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G.

Haematologica. 2013 Feb;98(2):193-200. doi: 10.3324/haematol.2012.066480. Epub 2012 Aug 8.

2.

Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?

Bedewy AM, El-Maghraby SM.

Hematology. 2013 Jul;18(4):211-6. doi: 10.1179/1607845412Y.0000000067. Epub 2013 Jan 31.

PMID:
23394475
3.

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH.

Clin Cancer Res. 2009 Jul 15;15(14):4750-8. doi: 10.1158/1078-0432.CCR-09-0145. Epub 2009 Jul 7.

4.

Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.

Ther Drug Monit. 2011 Apr;33(2):244-50. doi: 10.1097/FTD.0b013e31820beb02.

PMID:
21311410
5.

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.

Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR.

Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31.

PMID:
23117072
6.

Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.

Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H.

Hematology. 2014 Apr;19(3):123-8. doi: 10.1179/1607845413Y.0000000102. Epub 2013 Nov 25.

PMID:
23683876
7.

Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.

Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-Forti G, Biasco G.

Pharmacol Res. 2013 Feb;68(1):1-6. doi: 10.1016/j.phrs.2012.10.015. Epub 2012 Nov 2.

PMID:
23127916
8.

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE.

Clin Pharmacol Ther. 2008 Feb;83(2):258-64. Epub 2007 Jun 13.

PMID:
17568400
9.

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.

Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R.

Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7.

PMID:
24581936
10.

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, Foroni L, Kottaridis PD, Müller MC, Pirmohamed M, Clark RE.

Blood. 2013 Jan 24;121(4):628-37. doi: 10.1182/blood-2012-01-405035. Epub 2012 Dec 5.

11.

Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.

Gromicho M, Magalhães M, Torres F, Dinis J, Fernandes AR, Rendeiro P, Tavares P, Laires A, Rueff J, Sebastião Rodrigues A.

Oncol Rep. 2013 Feb;29(2):741-50. doi: 10.3892/or.2012.2153. Epub 2012 Nov 28.

PMID:
23229016
12.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS.

J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.

PMID:
20385986
13.

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.

Vine J, Cohen SB, Ruchlemer R, Goldschmidt N, Levin M, Libster D, Gural A, Gatt ME, Lavie D, Ben-Yehuda D, Rund D.

Leuk Lymphoma. 2014 Nov;55(11):2525-31. doi: 10.3109/10428194.2014.893307. Epub 2014 Mar 19.

PMID:
24524306
14.

Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.

Vaidya S, Ghosh K, Shanmukhaiah C, Vundinti BR.

Eur J Pharmacol. 2015 Oct 15;765:124-30. doi: 10.1016/j.ejphar.2015.08.034. Epub 2015 Aug 21.

PMID:
26300393
15.

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, le Coutre P, Nagler A.

Eur J Haematol. 2014 Apr;92(4):283-8. doi: 10.1111/ejh.12235. Epub 2013 Dec 18.

PMID:
24215657
16.

Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.

Au A, Baba AA, Azlan H, Norsa'adah B, Ankathil R.

J Clin Pharm Ther. 2014 Dec;39(6):685-90. doi: 10.1111/jcpt.12197. Epub 2014 Jul 24.

PMID:
25060527
17.

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K.

Haematologica. 2013 Sep;98(9):1407-13. doi: 10.3324/haematol.2013.085167. Epub 2013 May 28.

18.

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX.

Blood. 2008 Sep 1;112(5):2024-7. doi: 10.1182/blood-2008-03-147744. Epub 2008 Jun 4.

19.

hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.

Ben Hassine I, Gharbi H, Soltani I, Teber M, Farrah A, Ben Hadj Othman H, Amouri H, Bellaaj H, Lakhal RB, Romdhane NB, Abbes S, Menif S.

Cancer Chemother Pharmacol. 2017 Apr;79(4):737-745. doi: 10.1007/s00280-017-3266-0. Epub 2017 Mar 12.

PMID:
28286932
20.

SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.

Singh O, Chan JY, Lin K, Heng CC, Chowbay B.

PLoS One. 2012;7(12):e51771. doi: 10.1371/journal.pone.0051771. Epub 2012 Dec 18.

Supplemental Content

Support Center